The Democratic Republic of the Congo (DRC) Ministry of Health (MOH) now reports 5,290 confirmed Bundibugyo virus cases across six provinces (Ituri, Nord-Kivu, Sud-Kivu, Bas-Uélé, Haut-Uélé, Tshopo) and 56 health zones.
In addition, 2,516 deaths for a 47.6% case fatality rate has been reported.
This week it was announced an immediate initial release of 70 000 doses of the Ervebo vaccine- which is licensed and recommended for use in outbreaks of Ebola virus disease (previously called Zaire ebolavirus).
Drug-resistant Gonorrhea: An urgent threat to public health worldwide
The allocation includes 20,000 doses for a Phase 3 clinical trial to understand the impact of the vaccine on the Bundibugyo virus, and 50,000 doses for frontline and health workers in line with the current recommendations of the WHO Strategic Advisory Group of Experts on Immunization (SAGE).
Efficacy is species-specific: Ervebo targets Zaire ebolavirus and has limited or uncertain cross-protection against other species such as Bundibugyo or Sudan.
Comments
Nothing yet. Say the first thing.
Sign in to join the conversation.